All News
If We Can’t Prevent RA, Can We at Least Prevent Difficult-to-Treat RA?
Two new studies presented this year tackle a key question: can our initial treatment choices influence who ends up in the difficult-to-treat category?
Read Article
EGPA relapse in MANDARA including OLE
Majority of relapses are asthma / sinonasal in nature
Of non-airway:
- arthralgia/myalgia
- sensory peripheral neuropathy
@RheumNow #ACR25 Abst1769 https://t.co/cPjjzl4RWS
Links:
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
CAR T flex for myositis 💪 LB14: Ongoing Phase 1 CD19 CAR T in refractory myositis ✅ Well-tolerated (low-grade CRS, transient cytopenias) 📈 11/11 improved MMT-8 (median +22 Day 85, +27 Day 169) 🔹 10/11 off myositis therapy at follow-up @RheumNow #ACR25 https://t.co/btOsIcHe0f
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
IgG4-RD continues to present in new and unusual ways
Hasbani et al. report 9 IgG4-RD patients with coronary artery involvement
RCA and LAD most affected
Seen on CTA
Majority received RTX
7/9 pt at least partially improved imaging on f/u
@RheumNow #ACR25 Abst 2531 https://t.co/Na0gdq3dgb
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
RESET-RA, RCT of vagus nerve stim (device that zaps pts in neck)
Marginal improvements in ACR20 at wk 12; trend in to improvement in unblinded part of study fwiw
Have never seen result that is more likely to be driven by plbo effect & unblinding 🤪
@RheumNow #ACR25 Abstr#2278 https://t.co/BlR570nv7k
Links:
Mike Putman EBRheum ( View Tweet)
MSK side effects of CAR-T, based on FAERS pharmacovigilance data (also see @DrGomezPuerta in @seminarthrheum https://t.co/LnwjU5aebs) #ACR25 ABST1731 @RheumNow https://t.co/kREEy3HLE9
Links:
David Liew drdavidliew ( View Tweet)
Adding social risk factors to the mix
Abstract 1917: WashU Rheumatology examined SRF screening in the clinic
🔹 50% screened once; 1/3 screened > 1
🔹 Core SRFs (finance, transport, housing, food) relatively stable
🔹 Biggest change over time: stress
@RheumNow #ACR25 https://t.co/oKlwMZ77nB
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Higashida-Konishi et al. RA. Insomnia and fatigue in >80%, depression in 13%. RA disease activity is associated with depression, fatigue, and insomnia. @RheumNow #ACR25 Abstr#2254 https://t.co/7SibPW6BBw
Richard Conway RichardPAConway ( View Tweet)
Hojiej et al. Prevalence and Impact of lifestyle factors in PsA. Lifestyle factors impacted disease activity. Cumulative effect of increasing number of factors @RheumNow #ACR25 Abstr#2309 https://t.co/oDGQyLBRDO
Richard Conway RichardPAConway ( View Tweet)
Macedo et al. Increasing exercise improved QoL in axSpA. Mobility limitation and obesity worsened it. At least to some degree these effects appear independent. @RheumNow #ACR25 Abstr#2326 https://t.co/Ei4cKTNHyn
Richard Conway RichardPAConway ( View Tweet)
A prediction model for RA-ILD in RA pts: is it possible?
Not quite yet!
Veterans Affairs RA registry 2700+ pts
5% of prevalent ILD
Associated w/
-GDF-15
-Pentraxin 3
No prediction for Incident disease
Needs more work to understand implications for practice
@RheumNow #ACR25 https://t.co/CmW72nybcQ
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Mimics of ANCA-associated vasculitis: How can we tell?
With increased disease awareness and more regular, accessible testing for anti-neutrophil cytoplasmic antibodies (ANCA), ANCA-associated vasculitis (AAV) has become an increasingly recognized clinical entity in rheumatologic https://t.co/LYRk0rHlzx
Dr. John Cush RheumNow ( View Tweet)
“I never thought I’d live to old age with MCTD, now I plan for it.”
This patient’s journey highlights the power of evolving therapies, resilience, and lifestyle adaptation to age well with chronic autoimmune disease.
Patient perspectives abstract #PP04
@rheumnow #ACR25
Jiha Lee JihaRheum ( View Tweet)
#ClinicalPearl
Pts w #SpA ex #PsA May have
👇
#sicca #dry #eyes #dry mouth
Inflamed gallbladder without calculi
👇
Can be associated w #autoimmune disease
#POTS can be initial presentation of #SjD
IgA vasculitis—May have #cancer
#Secrets & #Pearls #ACR25 @RheumNow @ACRheum https://t.co/4SAqVYjnrD
Janet Pope Janetbirdope ( View Tweet)
Passive transfer of Ab can occur w #IVIg
#Ab can occur from IVIg passive transfer incl HepB
IVIg - if pt has #cryoglobulins
👇
Can precipitate severe #cryo flare
#ClinicalPearl
Secrets & Pearls session
#ACR25 @RheumNow @ACRheum https://t.co/tTaSuVy1yQ
Janet Pope Janetbirdope ( View Tweet)
#1726 IA from immune checkpoint inhibitors (ICI) is a distinct autoimmune entity: T cell-driven but not antibody-mediated
irAE arthritis shows hyperactive, cytotoxic CD8+ T cells & metabolic reprogramming, unlike RA. IL-6, IL-12 & IFNα fuel this process. @RheumNow #ACR25
Mrinalini Dey DrMiniDey ( View Tweet)
#ClinicalPearl
#seroneg #arthritis often has
👇
#involvement of
1st toe IP joint
Look at the feet 🦶
@RheumNow @ACRheum #ACR25
#28T08
Session secrets &pearls Tues https://t.co/EfqkLsTKmt
Janet Pope Janetbirdope ( View Tweet)
Overview of the use of SARD-ILD by @drdavidliew covering the challenges, professionalism, explainability and interpretability. Think of using and validating AI in the same way we train our residents. The human interface still needed @RheumNow #ACR25 https://t.co/TYKud057ag
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
The Power of Gamma Delta T Cell for Autoimmunity https://t.co/wIMu5r7b3D
More on T Cell engagers , this time with gama delta T cell ( tiny but mighty ). Kate Roslin talks about advantages of this protocol. (No cytokines thus less toxicity).
@Yuz6Yusof
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
#ACR25 Please find my video interview with Dr Kate Rochlin on a novel Bi-specific T-cell engager (BiTE) in development which binds to pan-gamma delta T-cell instead of CD3 to minimise risk of cytokine release syndrome side effect. Abstr#1535 @RheumNow
https://t.co/MOmUm41cyA https://t.co/TgIUGgWGw5
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
